T-cell epitope peptide vaccines

Expert Review of Vaccines

Volumn 3, Issue 5, 2004, Pages 563-575

  Elsawa, Sherine F ^a   Rodeberg, David A ^b   Celis, Esteban ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Cancer; Peptide vaccines; T cell epitopes

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CD4 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD8 ANTIGEN; EPITOPE; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX7; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HELPER CELL; HUMAN; PRIORITY JOURNAL; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES; VACCINES, SUBUNIT;

EID: 7444251645     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.5.563     Document Type: Review

References (128)

1. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases, 1893. Clin. Orthop. (262), 3-11 (1991).
2. Chen C. Experimental vaccine strategies for cancer immunotherapy. J. Biomed. Sci. 5, 231-252 (1998).
3. Schuler G, Steinman RM. Dendritic cells as adjuvants for immune-mediated resestance to tumors. J. Exp. Med. 186, 1183-1187 (1997).
4. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. 4(3), 328-332 (1998).
5. Zinkernagel RM, Doherty PC. MHC-restricted cytotoxic T-cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv. Immunol. 27, 51-177 (1979).
6. Melief CJ, Kast WM. T-cell immunotherapy of cancer. Res. Immunol. 142, 425-429 (1991).
7. Greenberg PD. Adoptive T-cell therapy of tumors, mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49, 281-355 (1991).
8. Berke G. The binding and lysis of target cells by cytotoxic T-lymphocytes: molecular and cellular aspects. Ann. Rev. Immunol. 12, 735-773 (1994).
9. Nabholz M, MacDonald HR. Cytolytic T-lymphocytes. Ann. Rev. Immunol. 1, 273-305 (1983).
10. Grabbe S, Beissert S, Schwartz T, Granstein RD. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol. Today 16, 116-120 (1996).
11. Germain RN, Margulies DH. The biochemistry and cell biology of antigen processing and presentation. Ann. Rev. Immunol. 11, 403-450 (1993).
12. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T-lymphocytes is mediated by CD40-CD40L interactions. Nature 393 (6684), 480-483 (1998).
13. + T-helper and a T-killer cell. Nature 393(6684), 474-476 (1998).
14. Bennett SR, Carbone FR, Karamalis F et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393(6684), 478-480 (1998).
15. Toes RE, van der Voort EI, Schoenberger SP et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J. Immunol. 160(9), 4449-4456 (1998).
16. + T-cell memory. Science 297(5589), 2060-2063 (2002).
17. Giuntoli RL 2nd, Lu J, Kobayashi H, Kennedy R, Celis E. Direct costimulation of tumor-reactive CTL by helper T-cells potentiate their proliferation, survival, and effector function. Clin. Cancer Res. 8(3), 922-931 (2002).
18. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen-processing machines. Cell 106(3), 255-258 (2001).
19. Steinman RM. The dendritic cell system and its role in immunogenicity. Ann. Rev. Immunol. 9, 271-296 (1991).
20. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T-cell stimulation by dendritic cells. Ann. Rev. Immunol. 20, 621-667 (2002).
21. Brossart P, Bevan MJ. Presentation of exogenous protein antigens on major histocompatibility complex Class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Blood 90(4), 1594-1599 (1997).
22. Watts C. The exogenous pathway for antigen presentation on major histocompatibility complex Class II and CD1 molecules. Nature Immunol. 5(7), 685-692 (2004). Discusses the fates of T-cell epitopes.
23. Watts C, Amigorena S. Antigen traffic pathways in dendritic cells. Traffic 1(4), 312-317 (2000).
24. Ackerman AL, Cresswell P. Cellular mechanisms governing cross-presentation of exogenous antigens. Nature Immunol. 5(7), 678-684 (2004).
25. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 23(9), 445-449 (2002). Highlights the importance of dendritic cells (DCs) in tolerance and immunity.
26. Ohodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T-cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193(2), 233-238 (2001).
27. Jonuleit H, Giesecke-Tuettenberg A, Turing T et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer 93(2), 243-251 (2001).
28. + T-cell help. J. Exp. Med, 186, 65-70 (1997).
29. Clarkson B, Strife A, Wisniewski D, Lambek CL, Liu C. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Leukemia 17(7), 1211-1262 (2003).
30. Chi N, Epstein JA. Getting your Pax straight: Pax proteins in development and disease. Trends Genet. 18(1), 41-47 (2002).
31. Horoszewicz J, Leong S, Kawinski E et al. LNCaP model of human prostatic carcinoma. Cancer Res. 43, 1809-1818 (1983).
32. Pretlow T, Wolman S, Micale M et al. Xenografts of primary human prostataic carcinoma. J. Natl Cancer Inst. 85, 394-398 (1993).
33. Nagabhushan M, Miller C, Pretlow T et al. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res. 56, 3042-3046 (1996).
34. van Weerden W, de Ridder C, Verdaasdonk C et al. Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am. J. Pathol. 149, 1055-1062 (1996).
35. Klein K, Reiter R, Redula J et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nature Med. 3, 402-408 (1997).
36. Rooney CM, Heslop HE, Brenner MK. EBV specific CTL: a model for immune therapy. Vox Sang. 74(Suppl. 2), 497-498 (1998).
37. Coulie PG. Human tumour antigens recognized by T-cells: new perspectives for anticancer vaccines? Mol. Med. Today 3(6), 261-268 (1997).
38. Kawakami Y, Rosenberg SA. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immunogene therapy. Int. Rev. Immunol. 14(2-3), 173-192 (1997).
39. Toes RE, Offringa R, Feltkamp MC et al. Tumor rejection antigens and tumor specific cytotoxic T-lymphocytes. Behring Inst. Mitt. (94), 72-86 (1994).
40. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T-lymphocytes. Ann. Rev. Immunol. 12, 337-365 (1994).
41. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4(3), 321-327 (1998).
42. Thurner B, Haendle I, Roder C et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T-cells and induces regression of some metastases in advanced Stage IV melanoma. J. Exp. Med. 190(11), 1669-1678 (1999).
43. Rosenberg SA, Packard BS, Aebersold PM et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319(25), 1676-1680 (1988).
44. Heslop HE, Rooney CM. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol. Rev. 157, 217-222 (1997).
45. Porgador A, Gilboa E. Bone-marrow generated dendritic cells pulsed with a Class-1-restricted peptide are potent inducers of cytotoxic T-lymphocytes. J. Exp. Med. 182, 255-260 (1995).
46. Mayordomo JL, Zorina T, Storkus W et al. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumour immunity. Nature Med. 1, 1297-1302 (1995).
47. Lu J, Celis E. Use of two predictive algorithms of the worldwide web for the identification of tumor-reactive T-cell epitopes. Cancer Res. 60(18), 5223-5227 (2000). Demonstrates the success of computer algorithms in epitope identification.
48. Lu J, Celis E. Recognition of prostate tumor cells by cytotoxic T-lymphocytes specific for prostate-specific membrane antigen. Cancer Res. 62, 5807 (2002).
49. Marchand M, Weynants P, Rankin E et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Internatl. J. Cancer 63, 883-885 (1995).
50. Jager E, Ringhoffer M, Dienes H et al. Granulocyte-macrophage colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Internatl J. Cancer 67, 54-62 (1996).
51. Weber J, Hua F, Spears L et al. A Phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J. Immunother. 22, 431-440 (1999).
52. + T-cell reactivity to a model tumor antigen. J. Immunol. 164, 562-565 (2000).
53. + T-cell responses in antitumor immunity. Curr. Opin. Immunol. 10, 588-594 (1998). Discusses the importance of T-Helper cells.
54. Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T-cells and their role in antitumor immune responses. J. Exp. Med. 189, 753-756 (1999).
55. Riddell SR, Greenberg PD. Principles for adoptive T-cell therapy of human viral diseases. Ann. Rev. Immunol. 13, 545 (1995).
56. Riddell SR, Watanabe KS, Goodrich JM et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones. Science 257, 238 (1992).
57. Heslop HE, Ng CY, Li C et al. Long-term restoration of immunity against Epsteinbarr virus infection by adoptive transfer of gene-modified virus-specific T-lymphocytes. Nature Med. 2, 551 (1996).
58. Kobayashi H, Wood M, Song Y, Appella E, Celis E. Defining promiscuous MHC Class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res. 60(18), 5228-5236 (2000).
59. Kobayashi H, Lu J, Celis E. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen. Cancer Res. 61(20), 7577-7584 (2001).
60. Kobayashi H, Song Y, Hoon DS, Appella E, Celis E. Tumor-reactive T-helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex Class II alleles. Cancer Res. 61(12), 4773-4778 (2001).
61. Kobayashi H, Omiya R, Ruiz M et al. Identification of an antigenic epitope for helper T-lymphocytes from carcinoembryonic antigen. Clin. Cancer Res. 8(10), 3219-3225 (2002).
62. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50(3-4), 213-219 (1999).
63. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T-cells. Cancer Immunol. Immunother. 50(1), 3-15 (2001).
64. Boon T, De Plaen E, Lurquin C et al. Identification of tumor rejection antigens recognized by T-lymphocytes. Cancer Surv. 13, 23-37 (1992).
65. Kawakami Y, Nishimura MI, Restifo NP et al. T-cell recognition of human melanoma antigens. J. Immunother. 14(2), 88-93 (1993).
66. Slingluff CL Jr, Hunt DF, Engelhard VH. Direct analysis of tumor-associated peptide antigens. Curr. Opin. Immunol. 6(5), 733-740 (1994).
67. Celis E, Sette A, Grey HM. Epitope selection and development of peptide-based vaccines to treat cancer. Semin. Cancer Biol. 6(6), 329-336 (1995). Discusses peptide vaccines for cancer.
68. Tureci O, Sahin U, Pfreundschuh M. Serological analysis of human tumor antigens: molecular definition and implications. Mol. Med. Today 3(8), 342-349 (1997).
69. Hartmann TB, Thiel D, Dummer R, Schadendorf D, Eichmuller S. SEREX identification of new tumor-associated antigens in cutaneous T-cell lymphoma. Br. J. Dermatol. 150(2), 252-258 (2004).
70. Greiner J, Ringhoffer M, Taniguchi M et al. Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. Int. J. Cancer 106(2), 224-231 (2003).
71. Minenkova O, Pucci A, Pavoni E et al. Identification of tumor-associated antigens by screening phage-displayed human cDNA libraries with sera from tumor patients. Int. J. Cancer 106(4), 534-544 (2003).
72. Li G, Miles A, Line A, Rees RC. Identification of tumor antigens by serological analysis of cDNA expression cloning. Cancer Immunol. Immunother. 53(3), 139-143 (2004).
73. Weinschenk T, Gouttefangeas C, Schirle M et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 62(20), 5818-5827 (2002).
74. Schag K, Schmidt SM, Muller MR et al. Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes. Clin. Cancer Res. 10(11), 3658-3666 (2004).
75. Schmidt SM, Schag K, Muller MR et al. Induction of adipophilin-specific cytotoxic T-lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res. 64(3), 1164-1170 (2004).
76. Rammensee HG, Falk K, Rotzschke O. Peptides naturally presented by MHC Class I molecules. Ann. Rev. Immunol. 11, 213-244 (1993).
77. Rammensee HG, Falk K, Rotzschke O. MHC molecules as peptide receptors. Curr. Opin. Immunol. 5(1), 35-44 (1993).
78. Kawashima I, Tsai V, Southwood S et al. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells. Int. J. Cancer 78(4), 518-524 (1998).
79. Celis E, Tsai V, Crimi C et al. Induction of antitumor cytotoxic T-lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl Acad. Sci. USA 91(6), 2105-2109 (1994).
80. Tsai V, Southwood S, Sidney J et al. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol. 158(4), 1796-1802 (1997).
81. Kawashima I, Hudson SJ, Tsai V et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum. Immunol. 59(1), 1-14 (1998).
82. Kawashima I, Tsai V, Southwood S et al. Identification of HLA-A3-restricted cytotoxic T-lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res. 59(2), 431-435 (1999).
83. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes. Immunity 10(6), 673-679 (1999).
84. Minev B, Hipp J, Firat H et al. Cytotoxic T-cell immunity against telomerase reverse transcriptase in humans. Proc. Natl Acad. Sci. USA 97(9), 4796-4801 (2000).
85. Ayyoub M, Migliaccio M, Guillaume P et al. Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T-cells from melanoma patients reveals inefficient antigen processing. Eur. J. Immunol. 31(9), 2642-2651 (2001).
86. Speiser DE, Cerottini JC, Romero P. Can hTERT peptide (540-548)-specific CD8 T-cells recognize and kill tumor cells? Cancer Immun. 2, 14 (2002).
87. Parkhurst MR, Riley JP, Igarashi T et al. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T-lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin. Cancer Res. 10(14), 4688-4698 (2004).
88. Melief CJ, Offringa R, Toes RE, Kast WM. Peptide-based cancer vaccines. Curr. Opin. Immunol. 8(5), 651-657 (1996).
89. Buteau C, Markovic SN, Celis E. Challenges in the development of effective peptide vaccines for cancer. Mayo Clin. Proc. 77(4), 339-349 (2002). Reviews the problems associated with peptide vaccines.
90. Southwood S, Sidney J, Kondo A et al. Several common HLA-DR types share largely overlapping peptide-binding repertoires. J. Immunol. 160(7), 3363-3373 (1998).
91. + T-cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun. 3, 15 (2003).
92. Widmann C, Romero P, Marjanski J, Coradin G, Valmori D. T-helper epitopes enhance the cytotoxic response of mice immunized with MHC Class I-restricted malaria peptides. Immunol. Meth. 155, 95 (1992).
93. Kyburz D, Aichele P, Speiser DE et al. T-cell immunity after a viral infection versus T-cell tolerance induced by soluble viral peptides. Eur. J. Immunol. 23(8), 1956-1962 (1993).
94. Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl Acad. Sci. USA, 93(15), 7855-7860 (1996).
95. Schijns VE. Induction and direction of immune responses by vaccine adjuvants. Crit. Rev. Immunol. 21(1-3), 75-85 (2001).
96. Matzinger P. Tolerance, danger, and the extended family. Ann. Rev. Immunol. 12, 991-1045 (1994).
97. Medzhitov R. Toll-like receptors and innate immunity. Nature Rev. Immunol. 1(2), 135-145 (2001).
98. Janeway CA Jr, Medzhitov R. Innate immune recognition. Ann. Rev. Immunol. 20, 197-216 (2002).
99. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nature Med. 5(11), 1249-1255 (1999).
100. Hadden JW. T-cell adjuvants. Int. J. Immunopharmacol. 16(9), 703-710 (1994).
101. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim. Biophys. Acta 1589(1), 1-13 (2002).
102. Lipford GB, Bauer M, Blank C et al. CpG-containing synthetic oligonucleotides promote B and cytotoxic T-cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. 27(9), 2340-2344 (1997).
103. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl Acad. Sci. USA 94(20), 10833-10837 (1997).
104. Davila E, Celis E. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with antitumor activity. J. Immunol. 165(1), 539-547 (2000).
105. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256), 1734-1736 (1996).
106. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anticytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190(3), 355-366 (1999).
107. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nature Immunol. 3(7), 611-618 (2002).
108. Davila E, Kennedy R, Celis E. Generation of antitumor immunity by cytotoxic T-lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 63(12), 3281-3288 (2003).
109. Davila E, Velez MG, Heppelmann CJ, Celis E. Creating space: an antigen-independent, CpG-induced peripheral expansion of naïve and memory T-lymphocytes in a full T-cell compartment. Blood 100(7), 2537-2545 (2002).
110. Machiels JP, Reilly RT, Emens LA et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte-macrophage colony-stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 61(9), 3689-3697 (2001).
111. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594), 850-854 (2002).
112. Dummer W, Niethammer AG, Baccala R et al. T-cell homeostatic proliferation elicits effective antitumor autoimmunity. J. Clin. Invest. 110(2), 185-192 (2002).
113. Maine GN, Mule JJ. Making room for T-cells. J. Clin. Invest. 110(2), 157-159 (2002).
114. Emens LA, Jaffee EM. Cancer vaccines: an old idea comes of age. Cancer Biol. Ther. 2(4 Suppl. 1), S161-S168 (2003).
115. Tan JT, Dudl E, LeRoy E et al. IL-7 is critical for homeostatic proliferation and survival of naive T-cells. Proc. Natl Acad. Sci. USA 98(15), 8732-8737 (2001).
116. Parrish-Novak J, Foster DC, Holly RD, Clegg CH. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T-cell responses. J. Leukoc. Biol. 72(5), 856-863 (2002).
117. DiGiacomo A, North RJ. T-cell suppressors of antitumor immunity. The production of Ly-1-,2+ suppressors of delayed sensitivity precedes the production of suppressors of protective immunity. J. Exp. Med. 164(4), 1179-1192 (1986).
118. Awwad M, North RJ. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res. 49(7), 1649-1654 (1989).
119. Awwad M, North RJ. Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of established tumors. Cancer Res. 50(8), 2228-2233 (1990).
120. Glaser M. Regulation of specific cell-mediated cytotoxic response against SV40-induced tumor-associated antigens by depletion of suppressor T-cells with cyclophosphamide in mice. J. Exp. Med. 149(3), 774-779 (1979).
121. Milton JD, Carpenter CB, Addison IE. Depressed T-cell reactivity and suppressor activity of lymoid cells from cyclophosphamide-treated mice. Cell. Immunol. 24(2), 308-317 (1976).
122. + regulatory T-cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34(2), 336-344 (2004).
123. + T-cells. J. Surg. Oncol. 67(4), 221-227 (1998).
124. + T-lymphocytes in antitumor immunity. Adv. Cancer Res. 87, 195-249 (2003).
125. Mackensen A, Herbst B, Chen JL et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int. J. Cancer 86(3), 385-392 (2000).
126. Overwijk WW, Restifo NP. Autoimmunity and the immunotherapy of cancer: targeting the 'self' to destroy the 'other'. Crit. Rev. Immunol. 20(6), 433-450 (2000).
127. Banchereau J, Palucka AK, Dhodapkar M et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61(17), 6451-6458 (2001).
128. Corbo M, Balmaceda C. Peripheral neuropathy in cancer patients. Cancer Invest. 19(4), 369-382 (2001).